HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Gastroenterology2365 papers

Inflammatory bowel disease

Last edited: 4/23/2026

Overview

Inflammatory bowel disease (IBD) encompasses Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the gastrointestinal tract leading to symptoms such as abdominal pain, diarrhea, and extraintestinal manifestations. 1 3

Diagnosis

Clinical Presentation: Abdominal pain, diarrhea, rectal bleeding, weight loss.

Laboratory Tests: Elevated inflammatory markers (CRP, ESR), fecal calprotectin.

Endoscopy: Essential for diagnosis; mucosal appearance guides differentiation between CD and UC. 29 30

Imaging: CT enterography, MRI enterography for CD; colonoscopy with biopsies for histopathological confirmation. 29

Genetic Testing: Not routinely required but may aid in diagnosis in specific cases. 4

Management

First-Line Treatments:

- 5-ASA Agents: For mild to moderate UC (e.g., mesalamine). - Antibiotics: For CD complications like fistulas (e.g., metronidazole, ciprofloxacin). - Aminosalicylates: For mild UC flares.

Advanced Therapies:

- Immunomodulators: Azathioprine, 6-mercaptopurine for maintenance of remission. - Biologics: Anti-TNF agents (e.g., infliximab, adalimumab), integrin receptor antagonists (e.g., vedolizumab), JAK inhibitors (e.g., tofacitinib).

Therapeutic Endoscopy: Considered for specific complications like strictures, bleeding, and fistulas. 6

Special Populations

Pregnancy: Maintain remission with thiopurines or avoid biologics; consider switching to methotrexate or budesonide if necessary. 4 34

Pediatrics: Focus on growth monitoring, tailored therapy (e.g., biologic use with caution), and therapeutic drug monitoring. 7 28

Elderly: Consider polypharmacy risks, efficacy of biologics, and potential for increased adverse events; prioritize treat-to-target strategies. 62 63

Comorbidities: Increased vigilance for thromboembolic events, metabolic dysfunction-associated steatotic liver disease, and arthritis. 17 51

Key Recommendations

Treat-to-Target Strategy: Aim for mucosal healing and symptom control using a combination of pharmacological and endoscopic monitoring. (Evidence: Strong 8)

Thromboprophylaxis: Consider prophylactic anticoagulation in high-risk IBD patients, especially those with prior thromboembolic events. (Evidence: Moderate 17)

Nutritional Support: Regular assessment and intervention for nutritional deficiencies, particularly vitamin D and micronutrients, in IBD patients. (Evidence: Moderate 69)

Adherence to Therapy: Enhance patient education and support to improve adherence, especially with complex regimens involving biologics and immunomodulators. (Evidence: Expert opinion 22)

Transition Care: Ensure structured transition programs for pediatric IBD patients moving to adult care, focusing on continuity of care and patient education. (Evidence: Expert opinion 33)

References

Showing 100 most recent of 954 indexed papers.

1 Cohen-Mekelburg S, Hashash JG, Loftus EV, Rubin DT. AGA Clinical Practice Update on Inpatient Management of Adults With Inflammatory Bowel Disease: Expert Review. Gastroenterology 2026. link 2 Wu X, Jiang J, Lu Q. Caffeine and IBD Risk: A Meta-Analysis. Journal of gastroenterology and hepatology 2026. link 3 El-Hussuna A, Hauer AC, Karakan T, Pittet V, Yanai H, Devi J et al.. ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries. Journal of Crohn's & colitis 2026. link 4 Qi HM, Liu TT, Chen JY, Wang YH, Mao XT, Wang YC et al.. Investigating the shared genetic architecture between inflammatory bowel disease and pancreatitis: a genome-wide cross-trait analysis. Molecular genetics and genomics : MGG 2026. link 5 Upadhyay N, Vadhariya A, Gorritz M, Tuly R, Sun K, Fisher DA et al.. Geographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States. Clinical and translational gastroenterology 2026. link 6 Kochhar GS, Coelho-Prabhu N, Hashash JG, Shen B. AGA Clinical Practice Update on the Role of Therapeutic Endoscopy in Inflammatory Bowel Disease: Commentary. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026. link 7 Turner D, Assa A, Malham M, Bar-Asher SY, Rayan C, Hyams JS et al.. Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN-NASPGHAN position paper. Journal of pediatric gastroenterology and nutrition 2026. link 8 Singh S, Oliver BJ, Hou JK, Lum D, Van Deen W, Harvey S et al.. Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study. Inflammatory bowel diseases 2026. link 9 Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S et al.. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026. link 10 Khenner E, Maddux M, Paseka S, Chevalier RL. Living with "Bathroom Issues": Inflammatory Bowel Disease in Pediatric and Adolescent Athletes. Current sports medicine reports 2026. link 11 Lin Y, Qin X, Zhang H, Huang J. Association Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses. Canadian journal of gastroenterology & hepatology 2026. link 12 Zimba O, Korkosz M, Sultanov A, Permenov BA, Kocyigit BF. Varicose veins and venous thromboembolism in inflammatory rheumatic diseases: vascular complications and rehabilitation approaches. Rheumatology international 2026. link 13 Liu W, Wang S, Wang G, Qiao Z, Rao L, Cheng L et al.. Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004-2024). Frontiers in immunology 2026. link 14 Iwayama K, Manabe T, Arai Y, Wakata Y, Oikawa G, Yamamoto M et al.. Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database. In vivo (Athens, Greece) 2026. link 15 Cantisán-Campillos R, García-Jambrina M, Martínez-Bermúdez E, González-Garay RS, Guillem Ferrer C, Majluf EE et al.. An atypical side effect of TNF alpha inhibitors: acute pleuropericarditis. Revista espanola de enfermedades digestivas 2026. link 16 Tamimi TA, Abu-Farsakh N, AlRyalat SA, Obeidat K, Ali SD, Hameed H et al.. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease. European journal of gastroenterology & hepatology 2026. link 17 Matthews T, Connor SM, Tyrrell H, Wilson R, Barry C, Billur A et al.. Inpatient and post-discharge thromboembolic events in inflammatory bowel disease patients: a 13 year retrospective cohort study at a tertiary Centre. Scandinavian journal of gastroenterology 2026. link 18 Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V et al.. Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026. link 19 Dawwas GK, Cuker A, Lewis JD. Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism. Blood advances 2026. link 20 Rolph MJ, Bolfa P, Cavanaugh SM, Hilchie D, Rolph KE. Detection of intracellular bacteria in feline inflammatory cardiac, hepatic and renal diseases: a retrospective study using fluorescent in situ hybridisation. Journal of feline medicine and surgery 2026. link 21 Shen Y, Jiang Y, Wang Y, Xu C, Wang X, Huang X. Increased risk of venous thromboembolism in children and teenagers with inflammatory bowel disease: a systematic review and meta-analysis. PeerJ 2026. link 22 Kucharzik T, Taylor S, Allocca M, Burisch J, Ellul P, Iacucci M et al.. ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. Journal of Crohn's & colitis 2025. link 23 Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F et al.. ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. The American journal of gastroenterology 2025. link 24 Moran GW, Gordon M, Sinopolou V, Radford SJ, Darie AM, Vuyyuru SK et al.. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut 2025. link 25 Shehab M, Al-Hindawi A, Alrashed F, Murthy S, Bisschops R, Hoentjen F et al.. Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics 2025. link 26 Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J et al.. Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. Inflammatory bowel diseases 2025. link 27 Caldera F, Kane S, Long M, Hashash JG. AGA Clinical Practice Update on Noncolorectal Cancer Screening and Vaccinations in Patients With Inflammatory Bowel Disease: Expert Review. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025. link 28 Felipez LM, Ali S, de Zoeten EF, Griffiths AM, Kim SC, Patel AS et al.. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition 2025. link 29 Shen B, Abreu MT, Cohen ER, Farraye FA, Fischer M, Feuerstadt P et al.. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointestinal endoscopy 2025. link 30 Bramuzzo M, Renzo S, Labriola F, Arrigo S, Lega S, Miele E et al.. Endoscopic assessment and scoring in pediatric inflammatory bowel disease: A consensus from SIGENP. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025. link 31 Mañosa M, Calafat M, Francia E, Riba F, Mesonero F, Suárez C et al.. GETECCU position paper on fragility, advanced age and inflammatory bowel disease. Gastroenterologia y hepatologia 2025. link 32 Chetwood JD, Arzivian A, Tran Y, Paramsothy S, Leong RW. Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics 2025. link 33 Vernon-Roberts A, Chan P, Christensen B, Havrlant R, Giles E, Williams AJ. Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand. Inflammatory bowel diseases 2025. link 34 Joudaki S, Oladipupo O, Carbery I, Lenti MV, Selinger CP. Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy. Alimentary pharmacology & therapeutics 2025. link 35 Song JH, Shim SR, Kim DS, Koo HS, Huh KC. Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of gastroenterology and hepatology 2025. link 36 Wang Q, Li S, Gu J, Yang J, Chen J, Cheng H et al.. Experiences and Perceptions of Food Avoidance in Patients With Inflammatory Bowel Disease: A Qualitative Meta-Synthesis. The journal of nursing research : JNR 2025. link 37 Xie Y, Chen ZS. A caged drug enables precision delivery. Science (New York, N.Y.) 2025. link 38 George AT, Rubin DT. Artificial Intelligence in Inflammatory Bowel Disease. Gastrointestinal endoscopy clinics of North America 2025. link 39 Kochhar GS, Dziegielewski C, Schairer JN, Cross RK. Role of Endoscopy in Inflammatory Bowel Disease: What Every Gastroenterologist Should Know. The American journal of gastroenterology 2025. link 40 Ran J, Zhou M, Wen H. Artificial intelligence in inflammatory bowel disease. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 2025. link 41 Devi J, Jena A, Hassan A, Lohia R, Catalan-Serra I, Sharma V et al.. Global Training in Inflammatory Bowel Disease: Addressing Growing Challenges in IBD. Digestive diseases and sciences 2025. link 42 Carvajal F, Herrera K, Núñez P, Flores L, Córdova A, Pizarro G et al.. Challenges in adherence to STRIDE-II: Perspectives from gastroenterologists and patients with inflammatory bowel disease. Gastroenterologia y hepatologia 2025. link 43 Laharie D, Vuitton L, Bourreille A, Bouhnik Y, Colombel JF, Louis E et al.. The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease. Journal of Crohn's & colitis 2025. link 44 Dhaliwal G, Dahiya DS, Dhaliwal AS, Ali H, Gangwani MK, Jaber F et al.. Understanding Role of Nutrition in Inflammatory Bowel Disease: A Comprehensive Review With Incorporation of AGA Update. Journal of gastroenterology and hepatology 2025. link 45 Kudo T, Arai K, Iwama I, Hagiwara SI, Ishige T, Yokoyama K et al.. Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan. Journal of gastroenterology 2025. link 46 Abdelrahman MSI, Abdeltawab D, Hamed Shehata R. Nailfold capillaroscopy in inflammatory bowel disease: A shared approach in gastroenterology and rheumatology. Reumatologia clinica 2025. link 47 Pugliese N, Bezzio C, Festa S, Caprioli FA, Renna S, Savarino EV et al.. Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey. European journal of gastroenterology & hepatology 2025. link 48 Zhang Y, Wan XH, Kong QZ, Liu H, Liu J, Guo J et al.. Evaluating large language models as patient education tools for inflammatory bowel disease: A comparative study. World journal of gastroenterology 2025. link 49 Gros B, Peraza J, Bassi M, Sleiman J, Abdelhalim S, Park E et al.. Disparities in Gender and Race Representation Among Authors of Inflammatory Bowel Disease Clinical Trials. Journal of Crohn's & colitis 2025. link 50 Al Awadhi S, Al Hassani A, El Ouali S, Alam MB, Azar C, Georgopoulos F et al.. Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease. World journal of gastroenterology 2025. link 51 Scarallo L, Maniscalco V, Marrani E, Aloi M, Alvisi P, Arrigo S et al.. Prevalence and outcomes of arthritis in pediatric IBD: A multicenter study from the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025. link 52 Hauer AC, Sultan M, Darma A, Altamimi E, Serban DE, Assa A et al.. Management of pediatric inflammatory bowel diseases in limited-resource settings: A position paper from the Paediatric IBD Porto Group of ESPGHAN. Journal of pediatric gastroenterology and nutrition 2025. link 53 Malter L, Hong SJ, Lopatin S, Murphy M, Hudesman D, Kane S et al.. Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience. Inflammatory bowel diseases 2025. link 54 Di Paolo MC, Cassinotti A, Pagnini C, Ceccarelli L, Mocci G, Luppino I et al.. Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists. European journal of gastroenterology & hepatology 2025. link 55 Casanova MJ, Gisbert JP, Amiot A, Gordon H, Fiorino G, Flanagan E et al.. International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements. United European gastroenterology journal 2025. link 56 von der Decken CB, Kleinert S, Englbrecht M, Karberg K, Gauler G, Ronneberger M et al.. RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings. Rheumatology international 2025. link 57 Gupta N, Ray M, Shayya A, McGinnis S, Marson J, Jagdeo J. Isotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis. Journal of drugs in dermatology : JDD 2025. link 58 Temido MJ, Honap S, Bursztejn AC, Portela F, Jairath V, Danese S et al.. Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. The American journal of gastroenterology 2025. link 59 Elali F, Nian P, Rodriguez AN, Conway CA, Saleh A, Razi AE. How Does Inflammatory Bowel Disease Impact Outcomes and Costs of Care Following Primary 1- to 2-level Lumbar Fusion for Degenerative Lumbar Disease?. Clinical spine surgery 2025. link 60 Yang Q, Huang F, Wang C, Liang X, Huang L, Xu H et al.. METTL3-mediated m. Annals of medicine 2025. link 61 Peerani F. Update in Inflammatory Bowel Disease Management in the Elderly. Current gastroenterology reports 2025. link 62 Drittel D, Schreiber-Stainthorp W, Delau O, Gurunathan SV, Chodosh J, Segev DL et al.. Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease. The American journal of gastroenterology 2025. link 63 Lund K, Ryg J, Knudsen T, Kjeldsen J, Nielsen J, Friedman S et al.. The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study. British journal of clinical pharmacology 2025. link 64 Czuber-Dochan W, Wileman V, Dibley L, Shankavi P, Fatima A, Norton C et al.. Process evaluation findings contradict RCT results of the IBD-BOOST digital self-management intervention for fatigue, pain and faecal urgency in inflammatory bowel disease: A mixed methods study of patient perspectives. British journal of health psychology 2025. link 65 Wileman V, Chilcot J, Norton C, Hart A, Miller L, Stagg I et al.. Modifiable Psychological Factors are Associated With Clusters of Pain, Fatigue, Fecal Incontinence, and Irritable Bowel Syndrome-Type Symptoms in Inflammatory Bowel Disease: A Latent Profile Analysis. Journal of Crohn's & colitis 2025. link 66 Roukas C, Miller L, Cléirigh Büttner F, Hamborg T, Stagg I, Hart A et al.. Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: A UK cross-sectional survey. United European gastroenterology journal 2025. link 67 Moss-Morris R, Norton C, Hart A, Cléirigh Büttner F, Hamborg T, Miller L et al.. Digital cognitive behavioural self-management programme for fatigue, pain, and faecal incontinence in inflammatory bowel disease (IBD-BOOST): a multicentre, parallel, randomised controlled trial. The Lancet. Digital health 2025. link 68 O'Donnell JEM, Leach ST, Bowcock NL, Chen S, Gupta N, Jiang K et al.. Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial. Digestive diseases and sciences 2025. link 69 Li H, Li WC, Hu XR. Association between vitamin C, D, and K intake and inflammatory bowel disease risk: findings from 2009 to 2010 NHANES. BMC gastroenterology 2025. link 70 Deng Y, Shi S, Feng S, Tan X, Wang Y, Yin J et al.. Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database. BMC gastroenterology 2025. link 71 König BH, Gosselt HR, van Lint JA, Kosse LJ, van den Bemt BJF, Ten Klooster PM et al.. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. Expert opinion on drug safety 2025. link 72 Tang Q, Tang X, Yin W, Li Y, Zhong X. Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. PloS one 2025. link 73 Zhan ZQ, Li JX, Chen YX, Fang JY. Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment. United European gastroenterology journal 2025. link 74 Xu Q, Zhang J, Tang W, Zhou M, Zhang X, Yuan P. Data mining and analysis of adverse events of Vedolizumab based on the FAERS database. Scientific reports 2025. link 75 Al Sulais E, Louis E, Bokemeyer B, Gecse KB, Parkes GC, Parkes M et al.. Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire. Journal of Crohn's & colitis 2025. link 76 Shi Y, Guan S, Wang S, Li M, Yu Y, Liu J et al.. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. PloS one 2025. link 77 Xu L, Huang Z, Chen G, Sun C, Yu Y, Gao S. Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS). European journal of medical research 2025. link 78 Mui NW, Uddin A, Fortunato MP, Nolan BE, Clare KM, Lui AK et al.. The gut-brain connection: Inflammatory bowel disease increases risk of acute ischemic stroke. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 2025. link 79 Niu C, Zhang J, Zhu K, Agbakoba G, Dunnigan K, Okolo PI. Cardiovascular complications during delivery hospitalizations in inflammatory bowel disease patients. Clinical research in cardiology : official journal of the German Cardiac Society 2025. link 80 Marín-Jiménez I, Carpio D, Hernández V, Muñoz F, Zatarain-Nicolás E, Zabana Y et al.. Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease. Gastroenterologia y hepatologia 2025. link 81 Meng MJ, Chung CS, Chang CW, Pan YB, Kuo CJ, Chiu CT et al.. The Incidence and Predictive Factors of Thromboembolism During Hospitalizations for Inflammatory Bowel Disease Flare-Ups: A Retrospective Cohort Study in Taiwan. Journal of evaluation in clinical practice 2025. link 82 Kim KJ, Song SB, Park JB, Bae JH, Baek JE, Kim GH et al.. Characteristics and outcomes of portal vein thrombosis in patients with inflammatory bowel disease in Korea. The Korean journal of internal medicine 2025. link 83 Richard N, Leroyer A, Ley D, Dupont C, Bertrand V, Wils P et al.. Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2025. link 84 Wen Z, Zhu L, He W, Liang T, Zhong Q, Long J et al.. Exploring the causal inference of inflammatory bowel disease and ischemic stroke: a bidirectional two-sample Mendelian randomization study. Journal of thrombosis and thrombolysis 2025. link 85 Shokravi A, Luo Y, Rabkin SW. Cellular and Molecular Mechanisms Explaining the Link Between Inflammatory Bowel Disease and Heart Failure. Cells 2025. link 86 Hashash JG, Elkins J, Lewis JD, Binion DG. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review. Gastroenterology 2024. link 87 Gordon M, Nigam GB, Sinopoulou V, Al Bakir I, Bateman AC, Din S et al.. Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease. BMJ open gastroenterology 2024. link 88 Zamani M, Alizadeh-Tabari S, Murad MH, Singh S, Ananthakrishnan AN, Malekzadeh R et al.. Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies. Alimentary pharmacology & therapeutics 2024. link 89 Keefer L, Hashash JG, Szigethy E, Mayer EA. AGA Clinical Practice Update on Pain Management in Inflammatory Bowel Disease: Commentary. Gastroenterology 2024. link 90 Tratenšek A, Locatelli I, Grabnar I, Drobne D, Vovk T. Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis. Redox biology 2024. link 91 Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory bowel diseases 2024. link 92 Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024. link 93 Feng Y, Feng W, Xu M, Wu C, Yang H, Wang Y et al.. Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis. Revista espanola de enfermedades digestivas 2024. link 94 Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Alimentary pharmacology & therapeutics 2024. link 95 Axelrad JE, Hashash JG, Itzkowitz SH. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024. link 96 Krishnamoorthy A, Chandrapalan S, Ahmed M, Arasaradnam RP. The Diagnostic Utility of Volatile Organic Compounds in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn's & colitis 2024. link 97 Zhang X, Zhu Z, Tang G, Xu H. The prevalence and risk factors of sexual dysfunction among females with inflammatory bowel disease: a systematic review and meta-analysis. International journal of impotence research 2024. link 98 Noviello CM. When a double negative is not a positive: Autoantibodies against IL-10 in patients with inflammatory bowel disease. Science immunology 2024. link 99 Huang JG. Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective. World journal of gastroenterology 2024. link 100 Van Eaton J, Hatch QM. Surgical Emergencies in Inflammatory Bowel Disease. The Surgical clinics of North America 2024. link

Original source

[1]
AGA Clinical Practice Update on Inpatient Management of Adults With Inflammatory Bowel Disease: Expert Review. — Cohen-Mekelburg S, Hashash JG, Loftus EV, Rubin DT Gastroenterology (2026)
[2]
Caffeine and IBD Risk: A Meta-Analysis. — Wu X, Jiang J, Lu Q Journal of gastroenterology and hepatology (2026)
[3]
ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries. — El-Hussuna A, Hauer AC, Karakan T, Pittet V, Yanai H, Devi J et al. Journal of Crohn's & colitis (2026)
[4]
Investigating the shared genetic architecture between inflammatory bowel disease and pancreatitis: a genome-wide cross-trait analysis. — Qi HM, Liu TT, Chen JY, Wang YH, Mao XT, Wang YC et al. Molecular genetics and genomics : MGG (2026)
[5]
Geographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States. — Upadhyay N, Vadhariya A, Gorritz M, Tuly R, Sun K, Fisher DA et al. Clinical and translational gastroenterology (2026)
[6]
AGA Clinical Practice Update on the Role of Therapeutic Endoscopy in Inflammatory Bowel Disease: Commentary. — Kochhar GS, Coelho-Prabhu N, Hashash JG, Shen B Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026)
[7]
Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN-NASPGHAN position paper. — Turner D, Assa A, Malham M, Bar-Asher SY, Rayan C, Hyams JS et al. Journal of pediatric gastroenterology and nutrition (2026)
[8]
Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study. — Singh S, Oliver BJ, Hou JK, Lum D, Van Deen W, Harvey S et al. Inflammatory bowel diseases (2026)
[9]
Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. — Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S et al. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026)
[10]
Living with "Bathroom Issues": Inflammatory Bowel Disease in Pediatric and Adolescent Athletes. — Khenner E, Maddux M, Paseka S, Chevalier RL Current sports medicine reports (2026)
[11]
Association Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses. — Lin Y, Qin X, Zhang H, Huang J Canadian journal of gastroenterology & hepatology (2026)
[12]
Varicose veins and venous thromboembolism in inflammatory rheumatic diseases: vascular complications and rehabilitation approaches. — Zimba O, Korkosz M, Sultanov A, Permenov BA, Kocyigit BF Rheumatology international (2026)
[13]
Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004-2024). — Liu W, Wang S, Wang G, Qiao Z, Rao L, Cheng L et al. Frontiers in immunology (2026)
[14]
Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database. — Iwayama K, Manabe T, Arai Y, Wakata Y, Oikawa G, Yamamoto M et al. In vivo (Athens, Greece) (2026)
[15]
An atypical side effect of TNF alpha inhibitors: acute pleuropericarditis. — Cantisán-Campillos R, García-Jambrina M, Martínez-Bermúdez E, González-Garay RS, Guillem Ferrer C, Majluf EE et al. Revista espanola de enfermedades digestivas (2026)
[16]
Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease. — Tamimi TA, Abu-Farsakh N, AlRyalat SA, Obeidat K, Ali SD, Hameed H et al. European journal of gastroenterology & hepatology (2026)
[17]
Inpatient and post-discharge thromboembolic events in inflammatory bowel disease patients: a 13 year retrospective cohort study at a tertiary Centre. — Matthews T, Connor SM, Tyrrell H, Wilson R, Barry C, Billur A et al. Scandinavian journal of gastroenterology (2026)
[18]
Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. — Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V et al. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026)
[19]
Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism. — Dawwas GK, Cuker A, Lewis JD Blood advances (2026)
[20]
Detection of intracellular bacteria in feline inflammatory cardiac, hepatic and renal diseases: a retrospective study using fluorescent in situ hybridisation. — Rolph MJ, Bolfa P, Cavanaugh SM, Hilchie D, Rolph KE Journal of feline medicine and surgery (2026)
[21]
Increased risk of venous thromboembolism in children and teenagers with inflammatory bowel disease: a systematic review and meta-analysis. — Shen Y, Jiang Y, Wang Y, Xu C, Wang X, Huang X PeerJ (2026)
[22]
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. — Kucharzik T, Taylor S, Allocca M, Burisch J, Ellul P, Iacucci M et al. Journal of Crohn's & colitis (2025)
[23]
ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. — Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F et al. The American journal of gastroenterology (2025)
[24]
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. — Moran GW, Gordon M, Sinopolou V, Radford SJ, Darie AM, Vuyyuru SK et al. Gut (2025)
[25]
Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease. — Shehab M, Al-Hindawi A, Alrashed F, Murthy S, Bisschops R, Hoentjen F et al. Alimentary pharmacology & therapeutics (2025)
[26]
Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. — Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J et al. Inflammatory bowel diseases (2025)
[27]
AGA Clinical Practice Update on Noncolorectal Cancer Screening and Vaccinations in Patients With Inflammatory Bowel Disease: Expert Review. — Caldera F, Kane S, Long M, Hashash JG Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025)
[28]
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease. — Felipez LM, Ali S, de Zoeten EF, Griffiths AM, Kim SC, Patel AS et al. Journal of pediatric gastroenterology and nutrition (2025)
[29]
Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. — Shen B, Abreu MT, Cohen ER, Farraye FA, Fischer M, Feuerstadt P et al. Gastrointestinal endoscopy (2025)
[30]
Endoscopic assessment and scoring in pediatric inflammatory bowel disease: A consensus from SIGENP. — Bramuzzo M, Renzo S, Labriola F, Arrigo S, Lega S, Miele E et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025)
[31]
GETECCU position paper on fragility, advanced age and inflammatory bowel disease. — Mañosa M, Calafat M, Francia E, Riba F, Mesonero F, Suárez C et al. Gastroenterologia y hepatologia (2025)
[32]
Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. — Chetwood JD, Arzivian A, Tran Y, Paramsothy S, Leong RW Alimentary pharmacology & therapeutics (2025)
[33]
Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand. — Vernon-Roberts A, Chan P, Christensen B, Havrlant R, Giles E, Williams AJ Inflammatory bowel diseases (2025)
[34]
Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy. — Joudaki S, Oladipupo O, Carbery I, Lenti MV, Selinger CP Alimentary pharmacology & therapeutics (2025)
[35]
Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. — Song JH, Shim SR, Kim DS, Koo HS, Huh KC Journal of gastroenterology and hepatology (2025)
[36]
Experiences and Perceptions of Food Avoidance in Patients With Inflammatory Bowel Disease: A Qualitative Meta-Synthesis. — Wang Q, Li S, Gu J, Yang J, Chen J, Cheng H et al. The journal of nursing research : JNR (2025)
[37]
A caged drug enables precision delivery. — Xie Y, Chen ZS Science (New York, N.Y.) (2025)
[38]
Artificial Intelligence in Inflammatory Bowel Disease. — George AT, Rubin DT Gastrointestinal endoscopy clinics of North America (2025)
[39]
Role of Endoscopy in Inflammatory Bowel Disease: What Every Gastroenterologist Should Know. — Kochhar GS, Dziegielewski C, Schairer JN, Cross RK The American journal of gastroenterology (2025)
[40]
Artificial intelligence in inflammatory bowel disease. — Ran J, Zhou M, Wen H Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association (2025)
[41]
Global Training in Inflammatory Bowel Disease: Addressing Growing Challenges in IBD. — Devi J, Jena A, Hassan A, Lohia R, Catalan-Serra I, Sharma V et al. Digestive diseases and sciences (2025)
[42]
Challenges in adherence to STRIDE-II: Perspectives from gastroenterologists and patients with inflammatory bowel disease. — Carvajal F, Herrera K, Núñez P, Flores L, Córdova A, Pizarro G et al. Gastroenterologia y hepatologia (2025)
[43]
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease. — Laharie D, Vuitton L, Bourreille A, Bouhnik Y, Colombel JF, Louis E et al. Journal of Crohn's & colitis (2025)
[44]
Understanding Role of Nutrition in Inflammatory Bowel Disease: A Comprehensive Review With Incorporation of AGA Update. — Dhaliwal G, Dahiya DS, Dhaliwal AS, Ali H, Gangwani MK, Jaber F et al. Journal of gastroenterology and hepatology (2025)
[45]
Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan. — Kudo T, Arai K, Iwama I, Hagiwara SI, Ishige T, Yokoyama K et al. Journal of gastroenterology (2025)
[46]
Nailfold capillaroscopy in inflammatory bowel disease: A shared approach in gastroenterology and rheumatology. — Abdelrahman MSI, Abdeltawab D, Hamed Shehata R Reumatologia clinica (2025)
[47]
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey. — Pugliese N, Bezzio C, Festa S, Caprioli FA, Renna S, Savarino EV et al. European journal of gastroenterology & hepatology (2025)
[48]
Evaluating large language models as patient education tools for inflammatory bowel disease: A comparative study. — Zhang Y, Wan XH, Kong QZ, Liu H, Liu J, Guo J et al. World journal of gastroenterology (2025)
[49]
Disparities in Gender and Race Representation Among Authors of Inflammatory Bowel Disease Clinical Trials. — Gros B, Peraza J, Bassi M, Sleiman J, Abdelhalim S, Park E et al. Journal of Crohn's & colitis (2025)
[50]
Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease. — Al Awadhi S, Al Hassani A, El Ouali S, Alam MB, Azar C, Georgopoulos F et al. World journal of gastroenterology (2025)
[51]
Prevalence and outcomes of arthritis in pediatric IBD: A multicenter study from the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition. — Scarallo L, Maniscalco V, Marrani E, Aloi M, Alvisi P, Arrigo S et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025)
[52]
Management of pediatric inflammatory bowel diseases in limited-resource settings: A position paper from the Paediatric IBD Porto Group of ESPGHAN. — Hauer AC, Sultan M, Darma A, Altamimi E, Serban DE, Assa A et al. Journal of pediatric gastroenterology and nutrition (2025)
[53]
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience. — Malter L, Hong SJ, Lopatin S, Murphy M, Hudesman D, Kane S et al. Inflammatory bowel diseases (2025)
[54]
Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists. — Di Paolo MC, Cassinotti A, Pagnini C, Ceccarelli L, Mocci G, Luppino I et al. European journal of gastroenterology & hepatology (2025)
[55]
International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements. — Casanova MJ, Gisbert JP, Amiot A, Gordon H, Fiorino G, Flanagan E et al. United European gastroenterology journal (2025)
[56]
RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings. — von der Decken CB, Kleinert S, Englbrecht M, Karberg K, Gauler G, Ronneberger M et al. Rheumatology international (2025)
[57]
Isotretinoin Does Not Increase the Risk of Inflammatory Bowel Disease: A TriNetX Retrospective Cohort Analysis. — Gupta N, Ray M, Shayya A, McGinnis S, Marson J, Jagdeo J Journal of drugs in dermatology : JDD (2025)
[58]
Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. — Temido MJ, Honap S, Bursztejn AC, Portela F, Jairath V, Danese S et al. The American journal of gastroenterology (2025)
[59]
How Does Inflammatory Bowel Disease Impact Outcomes and Costs of Care Following Primary 1- to 2-level Lumbar Fusion for Degenerative Lumbar Disease? — Elali F, Nian P, Rodriguez AN, Conway CA, Saleh A, Razi AE Clinical spine surgery (2025)
[60]
METTL3-mediated m — Yang Q, Huang F, Wang C, Liang X, Huang L, Xu H et al. Annals of medicine (2025)
[61]
Update in Inflammatory Bowel Disease Management in the Elderly. — Peerani F Current gastroenterology reports (2025)
[62]
Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease. — Drittel D, Schreiber-Stainthorp W, Delau O, Gurunathan SV, Chodosh J, Segev DL et al. The American journal of gastroenterology (2025)
[63]
The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study. — Lund K, Ryg J, Knudsen T, Kjeldsen J, Nielsen J, Friedman S et al. British journal of clinical pharmacology (2025)
[64]
Process evaluation findings contradict RCT results of the IBD-BOOST digital self-management intervention for fatigue, pain and faecal urgency in inflammatory bowel disease: A mixed methods study of patient perspectives. — Czuber-Dochan W, Wileman V, Dibley L, Shankavi P, Fatima A, Norton C et al. British journal of health psychology (2025)
[65]
Modifiable Psychological Factors are Associated With Clusters of Pain, Fatigue, Fecal Incontinence, and Irritable Bowel Syndrome-Type Symptoms in Inflammatory Bowel Disease: A Latent Profile Analysis. — Wileman V, Chilcot J, Norton C, Hart A, Miller L, Stagg I et al. Journal of Crohn's & colitis (2025)
[66]
Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: A UK cross-sectional survey. — Roukas C, Miller L, Cléirigh Büttner F, Hamborg T, Stagg I, Hart A et al. United European gastroenterology journal (2025)
[67]
Digital cognitive behavioural self-management programme for fatigue, pain, and faecal incontinence in inflammatory bowel disease (IBD-BOOST): a multicentre, parallel, randomised controlled trial. — Moss-Morris R, Norton C, Hart A, Cléirigh Büttner F, Hamborg T, Miller L et al. The Lancet. Digital health (2025)
[68]
Daily Vitamin D3 Versus Stoss Vitamin D3 for Correction of 25OHD Deficiency in Children with Inflammatory Bowel Disease, a Randomised Controlled Trial. — O'Donnell JEM, Leach ST, Bowcock NL, Chen S, Gupta N, Jiang K et al. Digestive diseases and sciences (2025)
[69]
Association between vitamin C, D, and K intake and inflammatory bowel disease risk: findings from 2009 to 2010 NHANES. — Li H, Li WC, Hu XR BMC gastroenterology (2025)
[70]
Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database. — Deng Y, Shi S, Feng S, Tan X, Wang Y, Yin J et al. BMC gastroenterology (2025)
[71]
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. — König BH, Gosselt HR, van Lint JA, Kosse LJ, van den Bemt BJF, Ten Klooster PM et al. Expert opinion on drug safety (2025)
[72]
Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. — Tang Q, Tang X, Yin W, Li Y, Zhong X PloS one (2025)
[73]
Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment. — Zhan ZQ, Li JX, Chen YX, Fang JY United European gastroenterology journal (2025)
[74]
Data mining and analysis of adverse events of Vedolizumab based on the FAERS database. — Xu Q, Zhang J, Tang W, Zhou M, Zhang X, Yuan P Scientific reports (2025)
[75]
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire. — Al Sulais E, Louis E, Bokemeyer B, Gecse KB, Parkes GC, Parkes M et al. Journal of Crohn's & colitis (2025)
[76]
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. — Shi Y, Guan S, Wang S, Li M, Yu Y, Liu J et al. PloS one (2025)
[77]
Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS). — Xu L, Huang Z, Chen G, Sun C, Yu Y, Gao S European journal of medical research (2025)
[78]
The gut-brain connection: Inflammatory bowel disease increases risk of acute ischemic stroke. — Mui NW, Uddin A, Fortunato MP, Nolan BE, Clare KM, Lui AK et al. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences (2025)
[79]
Cardiovascular complications during delivery hospitalizations in inflammatory bowel disease patients. — Niu C, Zhang J, Zhu K, Agbakoba G, Dunnigan K, Okolo PI Clinical research in cardiology : official journal of the German Cardiac Society (2025)
[80]
Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease. — Marín-Jiménez I, Carpio D, Hernández V, Muñoz F, Zatarain-Nicolás E, Zabana Y et al. Gastroenterologia y hepatologia (2025)
[81]
The Incidence and Predictive Factors of Thromboembolism During Hospitalizations for Inflammatory Bowel Disease Flare-Ups: A Retrospective Cohort Study in Taiwan. — Meng MJ, Chung CS, Chang CW, Pan YB, Kuo CJ, Chiu CT et al. Journal of evaluation in clinical practice (2025)
[82]
Characteristics and outcomes of portal vein thrombosis in patients with inflammatory bowel disease in Korea. — Kim KJ, Song SB, Park JB, Bae JH, Baek JE, Kim GH et al. The Korean journal of internal medicine (2025)
[83]
Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study. — Richard N, Leroyer A, Ley D, Dupont C, Bertrand V, Wils P et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025)
[84]
Exploring the causal inference of inflammatory bowel disease and ischemic stroke: a bidirectional two-sample Mendelian randomization study. — Wen Z, Zhu L, He W, Liang T, Zhong Q, Long J et al. Journal of thrombosis and thrombolysis (2025)
[85]
Cellular and Molecular Mechanisms Explaining the Link Between Inflammatory Bowel Disease and Heart Failure. — Shokravi A, Luo Y, Rabkin SW Cells (2025)
[86]
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review. — Hashash JG, Elkins J, Lewis JD, Binion DG Gastroenterology (2024)
[87]
Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease. — Gordon M, Nigam GB, Sinopoulou V, Al Bakir I, Bateman AC, Din S et al. BMJ open gastroenterology (2024)
[88]
Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies. — Zamani M, Alizadeh-Tabari S, Murad MH, Singh S, Ananthakrishnan AN, Malekzadeh R et al. Alimentary pharmacology & therapeutics (2024)
[89]
AGA Clinical Practice Update on Pain Management in Inflammatory Bowel Disease: Commentary. — Keefer L, Hashash JG, Szigethy E, Mayer EA Gastroenterology (2024)
[90]
Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis. — Tratenšek A, Locatelli I, Grabnar I, Drobne D, Vovk T Redox biology (2024)
[91]
Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. — Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP Inflammatory bowel diseases (2024)
[92]
AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary. — Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024)
[93]
Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis. — Feng Y, Feng W, Xu M, Wu C, Yang H, Wang Y et al. Revista espanola de enfermedades digestivas (2024)
[94]
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. — Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW Alimentary pharmacology & therapeutics (2024)
[95]
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary. — Axelrad JE, Hashash JG, Itzkowitz SH Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024)
[96]
The Diagnostic Utility of Volatile Organic Compounds in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. — Krishnamoorthy A, Chandrapalan S, Ahmed M, Arasaradnam RP Journal of Crohn's & colitis (2024)
[97]
The prevalence and risk factors of sexual dysfunction among females with inflammatory bowel disease: a systematic review and meta-analysis. — Zhang X, Zhu Z, Tang G, Xu H International journal of impotence research (2024)
[98]
When a double negative is not a positive: Autoantibodies against IL-10 in patients with inflammatory bowel disease. — Noviello CM Science immunology (2024)
[99]
Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective. — Huang JG World journal of gastroenterology (2024)
[100]
Surgical Emergencies in Inflammatory Bowel Disease. — Van Eaton J, Hatch QM The Surgical clinics of North America (2024)

Share:Twitter Reddit LinkedIn